Company intelligence / Profile preview

Libra Group

San Diego, California, United Stateslibra.com ↗

Ownership: Private
Development stage: Commercial

Overview

Libra Therapeutics develops novel, disease-modifying small molecules that restore cellular balance by improving lysosomal function and autophagy, aiming to halt or slow neurodegeneration. Their lead program targets TRPML1 and plans to enter clinical trials in ALS in the near future. The company operates virtually, partnering with CROs for all R&D activities. Backed by top-tier investors, it leverages proprietary technology from Axxam S.p.A.

Therapeutic areas: Neurology
Modalities: Small molecule
Industry: Biotech

Partnerships

Axxam S.p.A. – provides proprietary assays/chemical matter/platform technology

Beyond the preview

Go deeper on Libra Group.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Libra Group.

Explore the full profile